Overview

Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease

Status:
Withdrawn

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

This study will estimate the total time for the preparation and administration of denosumab and the total time for the preparation and administration of pamidronate.

Phase:

Phase 4

Details

Lead Sponsor:

Amgen

Treatments:

Denosumab
Pamidronate